Replies to post #203258 on Avid Bioservices Inc (CDMO)

[biopharm]

Dmitry Gabrilovich : Peregrine Pharmaceuticals KOL :

Talk: Immunosuppressive mechanisms in myeloid cells (49 min)

http://hstalks.com/main/view_talk.php?t=2956&r=494&j=755&c=252

----------------------------------------------------------

Ok, hopefully all have listened to the 49 min talk of Dmitry Gabrilovich above... and here again, we have some more details behind the what exactly happens in those initial stages of cancer....

How Tumor-Causing Cells are Recruited in Cancers Linked to Chronic Inflammatory Diseases

PHILADELPHIA — Chronic inflammation is directly associated with several types of cancer, yet the reasons why this happens at a cellular level remain unclear. Now, an international team of scientists led by researchers at the Wistar Institute has identified a multistep process showing how these cancers develop and potentially discovering new therapeutic targets that could halt the formation and progression of tumor cells.

The findings were published online by the Journal of Experimental Medicine.

While inflammation is an important part of how the body recovers from disease and injury, chronic inflammation has been linked to a variety of cancers, such as basal cell carcinoma, lung, liver, and colon cancer.

“While we know that cancer is initiated because of genetic alterations, we also know that cancer’s development relies heavily on environmental factors," said Dmitry Gabrilovich, MD, PhD, the Wistar Institute’s Christopher M. Davis Professor, professor and program leader of the Translational Tumor Immunology Program, and professor in the Tumor Microenvironment and Metastasis Program. “Inflammatory conditions are closely linked to cancer, yet it’s a very complex process, making it difficult to determine how certain components contribute to the development of cancer."

Gabrilovich and his fellow investigators demonstrated that inflammatory conditions are associated with a specific phenotype of myeloid cells called immature granulocytic cells.

Using transgenic mice that expressed this phenotype, Gabrilovich’s lab created conditions in which the granulocytic cells would accumulate in the absence of typical methods of inflammation, such as tissue damage or infection. When the mice were exposed to a tumor-promoting substance called TPA, the researchers observed a dramatic increase in the formation of benign tumors, or papillomas, usually among the first signs of the formation of skin cancer.

Gabrilovich and his team found that the granulocytic cells arrive at the skin and stimulate the migration of lymphocytes, which in turn stimulate the abnormal growth of keratinocytes, the most common type of skin cell found in the epidermis. The granulocytic cells are able to “recruit" these lymphocytes by releasing a specific factor called chemokine CCL4. This factor then recruits CD4+ T cells that produce interleukin-17 (IL-17), a proinflammatory cytokine that has already been linked to chronic inflammation and inflammatory cancers.

Through a series of steps, this study implicates that granulocytic cells accumulate and serve as the first step of tumor formation, followed by the recruitment of CD4+ T cells that produce IL-17. The combination of these events ultimately results in the development of cancer. While this study focused on skin cancer, Gabrilovich said that the study could apply to any type of cancer linked to chronic inflammation. If proven for other conditions this mechanism could open an opportunity for potential therapeutic targeting in patients with chronic inflammation that predispose a patient to cancer.

Source: Wistar Institute

http://www.endonurse.com/news/2015/02/how-tumor-causing-cells-are-recruited-in-cancers.aspx

..yes, you are not going to get all the info you need by just listening to the shifting arguments, arguments that have never once stated facts or links of reference or any digging deeper into why the science does not work with Bavituximab and PS Targeting. Do you ever ask yourself why that is so ?? I know why and it is because the science, safety, efficacy and synergistic, natural properties allow Bavi to be combined with many other BP platform drugs and those facts can't be argued no longer. So the arguments shift downstream.. further and further away from the science.

Though... you may hear about the BOD, the very same BOD that has brought "dozens of collaborations" and will the BOD actually reveal their plan in the middle of the biggest game of immunotherapy?? No way... not until they are ready.

Do you see your favorite sports team reveal their game plan before or in the middle of the game? No way!

Follow the science (Immuno-Oncology/PS Targeting) and follow the money (BlackRock)

Eventually... it can be figured out and who knows, maybe by ASCO time Adam Yopp will be allowed to give a few more puzzle pieces. All the Big Pharmas need an I/O pipeline so things will not be boring till then.

I know, you still ask why is it under $2 ??? Maybe because its more difficult to use margin and keeps a very low profile on the stock until shorts are all covered (they just about are!) and until more hop on board (BlackRock doing a fine job here!) and until manufacturing moves along (linkedin profiles say they are well on their way!) and until more data and data and data are incorporated into the BLA filing (per Garnick in progress and a big process it is...) and until they realize no more retail are going to fall for the same old games and be selling.

Now take your game to the next level and read up on Bavituximabs MOA, PS Targeting, MDSC's Myeloid Derived Suppressor Cells, Inflammation, chronic inflammation and how greedy Big Pharma has always been.